Chong Kun Dang

Duvie Tablet, an in-house glitazone-class diabetes treatment and the first drug of this class developed in Korea.

Nesbell, a biosimilar of the anemia drug Nesp, approved in Korea and also exported to Japan.

G-Tec, a botanical new drug for gastritis made from cinnamon bark extract and developed in-house from raw-material selection to finished product; in Phase 3 it showed superiority over the active comparator in improving gastric mucosal erosion.

T-cell epitope-based cancer vaccine partnered with OSE Immunotherapeutics of France, for HLA-A2-positive non-small cell lung cancer.

Production plant in Cheonan, Chungcheongnam-do, on a 146,296 m² site, where an automated warehouse system controls everything from raw-material dispensing to finished-product release; it has dedicated cephalosporin and penicillin lines and biopharmaceutical production capacity.

Signed a license agreement with Kiora Pharmaceuticals of the U.S. to develop, register and commercialize KIO-301, a small-molecule candidate for retinitis pigmentosa, in Korea.

Held a launch symposium in Seoul for G-Tec, its botanical new drug for gastritis, and presented the Phase 3 results.

Presented preclinical results for a degrader-antibody conjugate (DAC) candidate that degrades cyclin K at World ADC San Diego in the U.S., reporting that efficacy was maintained in cancer cells resistant to an existing ADC.